NASDAQ : ABVC
ABVC BioPharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 25.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 25.70M |
| Enterprise Value | 28.50M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 25.96M |
| Shares Outstanding | 25.96M |
| Shares Change (YoY) | +72.05% |
| Shares Change (QoQ) | +2.40% |
| Owned by Insiders (%) | 18.36% |
| Owned by Institutions (%) | 4.25% |
| Float | 21.14M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.48 |
| P/TBV Ratio | 2.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.07 |
| Quick Ratio | 0.02 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.98 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -69.86% |
| Return on Assets (ROA) | -22.85% |
| Return on Invested Capital (ROIC) | -30.36% |
| Return on Capital Employed (ROCE) | -47.54% |
| Weighted Average Cost of Capital (WACC) | 6.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$374,033 |
| Employee Count | 19 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 527 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -63.90% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 48.26 |
| Average Volume (20 Days) | 45,488 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 589,852 |
| Short Previous Month | 490,291 |
| Short % of Shares Out | 2.27% |
| Short % of Float | 2.79% |
| Short Ratio (days to cover) | 4.96 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.52M |
| Pretax Income | -7.60M |
| Net Income | -7.11M |
| EBITDA | -6.49M |
| EBIT | -6.52M |
| Earnings Per Share (EPS) | -$0.29 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 94,364 |
| Total Debt | 2.89M |
| Net Cash | -2.79M |
| Net Cash Per Share | -$0.11 |
| Equity (Book Value) | 12.27M |
| Book Value Per Share | 0.40 |
| Working Capital | -5.28M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.69M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 23,911 |
| Net Borrowing | -101,804 |
| Free Cash Flow | -2.69M |
| FCF Per Share | -$0.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -72.05% |
| Shareholder Yield | -72.05% |
| Earnings Yield | -28.84% |
| FCF Yield | -10.36% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |